Impact of Preanalytical Factors on Calprotectin Concentration in Stool
By LabMedica International staff writers Posted on 29 Dec 2022 |

In inflammatory bowel disease (IBD), fecal calprotectin measurement is increasingly important in selecting patients for diagnostic endoscopy, monitoring of disease activity, and evaluation of treatment response.
Calprotectin is a calcium-binding protein mainly produced in neutrophils. It is said to be resistant to bacterial degradation in the colon, and the literature almost unanimously states that calprotectin is stable up to seven days at room temperature without preservation buffer.
Clinical Chemists at the University Medical Center Groningen (Groningen, The Netherlands) and their colleagues from other institutions evaluated the impact of pre-analytical storage conditions on reliability of calprotectin testing using five different calprotectin immunoassays. The scientists distributed 45 frozen anonymized feces aliquots among the three participating centers. They assessed the calprotectin concentration over time under four conditions, including (a) untreated native stool stored at room temperature (NRT), (b), stool extract stored at room temperature, (c), untreated native stool stored at 4 °C, and (d), stool extract stored at 4 °C.
The five assays were: the Bühlmann fCAL turbo test (Bühlmann Laboratories AG, Schönenbuch Switzerland) is a particle-enhanced turbidimetric immunoassay performed on a COBAS 6000 e501 (Roche Diagnostics, Rotkreuz. Switzerland); the Bühlmann fCAL enzyme-linked immunosorbent assay (ELISA; Bühlmann Laboratories AG) is a sandwich-based ELISA performed and analyzed using a DS2 Dynex ELISA robot (Dynex, Chantilly, VA, USA); the CALliaGold test (Sentinel CH, Milan Italy) is a particle-enhanced turbidimetric immunoassay (PETIA) and analysis was performed using a SENTiFIT 270 Analyzer (Sysmex Europe SE, Norderstedt, Germany).
The other two assays were the EliA Calprotectin test which is a fluorescence enzyme immunoassay and the analysis was performed using the Phadia 250 (Thermo Fisher Scientific, Waltham, MA, USA); and the QUANTA Flash Calprotectin (Inova Diagnostics , San Diego, CA, USA) a chemiluminescent immunoassay and the analysis was performed on BIO FLASH (Werfen, Bedford, MA, USA).
The investigators reported that Calprotectin concentrations declined over time under all pre-analytical conditions with all assays, except for extracted feces stored at 4 °C. The rate of decline was greatest in untreated stool kept at room temperature, reaching significant difference from baseline already after one day. In extracted feces kept at room temperature, significant difference from baseline was reached after two days, and in untreated feces at 4 °C, after four days. However, the results differed significantly between assays. After four days of storage at room temperature, the mean calprotectin decline from baseline differed between 30% and 60%, dependent on the assay used. In most, but not for all samples, the CALiaGold assay produced the highest calprotectin levels, and the QUANTA flash assay, the lowest calprotectin levels.
The authors conclude that fecal calprotectin concentration in stool samples declines over time, and the rate of decline is greater at higher temperatures. In extracted feces stored at 4 °C, calprotectin is the most stable. It is assay-dependent how long extracted feces stored at 4 °C give reliable test results. The study was published in the November 2022 issue of The Journal of Applied Laboratory Medicine.
Related Links:
University Medical Center Groningen
Bühlmann Laboratories
Roche Diagnostics
Dynex
Sentinel CH
Sysmex
Thermo Fisher Scientific
Inova Diagnostics
Werfen
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
Channels
Clinical Chemistry
view channel
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
Children are experiencing metabolic problems at increasingly younger ages, placing them at higher risk for serious health issues later in life. There is a growing need to identify this risk from birth... Read more
Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
Parkinson’s disease is a neurodegenerative condition typically diagnosed at an advanced stage based on clinical symptoms, primarily motor disorders. However, by this time, the brain has already undergone... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreMicrobiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more